LoxiGen awarded three-year STTR grant to develop therapy for drug-resistant TNBC

USPSTF’s Wanda Nicholson: Final recommendation to start breast cancer screening at 40 will save 20% more lives

All women should start screening for breast cancer at age 40, with biennial screening continuing through age 74, the U.S. Preventive Services Task Force said in its final recommendation statement April 30.

May 03, 2024

Vol.50 No.18

By Matthew Bin Han Ong

Clinical Roundup

Enhertu improves PFS in HR-positive, HER2-low breast cancer in phase III trial

Positive high-level results from the DESTINY-Breast06 phase III trial showed that Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.

May 03, 2024

Vol.50 No.18

Clinical Roundup

Breast cancer screening tool predicts patient response to immunotherapies

By examining which genes were turned on and off in a mix of cell types from breast cancer biopsies, a team led by UT Southwestern Medical Center researchers developed a tool that can accurately predict which patients with breast cancer will respond to immunotherapies.

May 03, 2024

Vol.50 No.18

Clinical Roundup

PRMT5 inhibitor combination overcomes drug resistance in ER+ breast cancer

Shutting down a gene called PRMT5 stopped metastatic estrogen receptor-positive breast cancer cells from growing after they acquired resistance to a standard therapy known as CDK4/6 inhibitors, UT Southwestern Medical Center researchers showed in a new study.

April 26, 2024

Vol.50 No.17

Clinical Roundup

Radiation before mastectomy cuts time delays for reconstructive surgery in breast cancer patients

Researchers at MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays, and improved patient satisfaction.

April 12, 2024

Vol.50 No.15

In Brief

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

Antonio C. Wolff, chair of the Breast Cancer Committee for the ECOG-ACRIN Cancer Research Group, will co-lead the Breast Cancer Steering Committee for NCI. He began the three-year term on April 1.

April 05, 2024

Vol.50 No.14

LoxiGen awarded three-year STTR grant to develop therapy for drug-resistant TNBC

YOU MAY BE INTERESTED IN

USPSTF’s Wanda Nicholson: Final recommendation to start breast cancer screening at 40 will save 20% more lives

Enhertu improves PFS in HR-positive, HER2-low breast cancer in phase III trial

Breast cancer screening tool predicts patient response to immunotherapies

PRMT5 inhibitor combination overcomes drug resistance in ER+ breast cancer

Radiation before mastectomy cuts time delays for reconstructive surgery in breast cancer patients

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

Renew today!

Subscriber content

Login